DUBLIN, March 1, 2021 / PRNewswire / – Perrigo Company plc (NYSE; TASE: PRGO), a leading global supplier of personal care products, today announced that it has entered into a definitive agreement to sell its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for total consideration of $ 1.55 billion, including $ 1.5 billion in cash, subject to customary adjustments. As part of this reflection, Altaris will also assume more over $ 50 million in potential R&D milestone payments and conditional purchase obligations with third-party Rx partners.
Perrigo CEO and President Murray S. Kessler said, “The sale of our Generic Rx business is the most significant step in Perrigo’s transformation plan. This transaction makes Perrigo a global player in consumer self-care …
News Highlights Business
- Headline: Perrigo announces deal to sell generic Rx business for $ 1.55 billion in full consideration
- Check all news and articles from the Business news updates.